Menlo Park, California, February 10, 2011. 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer.
“Steve’s contributions have been pivotal as a member of the team during his tenure at 3-V,” said Merdad V. Parsey, MD, PhD, 3-V’s Chief Executive Officer. “I look forward to working with him as we continue to build the 3-V team and advance the company’s programs.”
Mr. Brady joined the 3-V team in 2010 as Vice President, Corporate Development, Strategy & Operations, with management responsibility for the company’s business functions, including strategy, finance and legal. Prior to joining the company, Mr. Brady was the Vice President of Corporate Development of Proteolix, Inc. where he had primary responsibility for Proteolix’s business development activities, resulting in the sale of the company to Onyx Pharmaceuticals, Inc. Previously, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served in business development, communications and corporate legal capacities. Prior to his tenure with Lexicon Pharmaceuticals, Inc., Mr. Brady was a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co., LLC, and an associate in the New York and San Francisco offices of Morrison & Foerster LLP. Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from the New York University School of Law.
3-V Biosciences, Inc. is a privately held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel therapeutics that target host cell factors required for infection, thereby avoiding many of the shortcomings of traditional pathogen directed approaches. The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates. For additional information on 3-V Biosciences, please visit www.3vbio.com.com